The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019.
EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. We work collaboratively with public sector and industry partners to translate the great science arising from Singapore’s biomedical and clinical sciences R&D into innovative healthcare solutions, with a focus on Asian-prevalent diseases.
EDDC possesses a full range of capabilities for the discovery and development of small molecule or antibody-based drugs and companion diagnostics. We are keen to engage with academic, clinical, and bio-pharmaceutical industry partners for development and commercialization of innovative assets and platforms. We want to jointly bring forward medicines that improve healthcare, and generate a return to support Singapore’s future drug discovery research.